IL256342B2 - מודל עכבר nsg מואנש עם שתלים ממקור של מטופלים שאינו תואם–hla - Google Patents

מודל עכבר nsg מואנש עם שתלים ממקור של מטופלים שאינו תואם–hla

Info

Publication number
IL256342B2
IL256342B2 IL256342A IL25634217A IL256342B2 IL 256342 B2 IL256342 B2 IL 256342B2 IL 256342 A IL256342 A IL 256342A IL 25634217 A IL25634217 A IL 25634217A IL 256342 B2 IL256342 B2 IL 256342B2
Authority
IL
Israel
Prior art keywords
mouse
human
cells
pdx
cancer
Prior art date
Application number
IL256342A
Other languages
English (en)
Other versions
IL256342B (he
IL256342A (he
Inventor
James Keck
Original Assignee
Jackson Lab
James Keck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson Lab, James Keck filed Critical Jackson Lab
Publication of IL256342A publication Critical patent/IL256342A/he
Publication of IL256342B publication Critical patent/IL256342B/he
Publication of IL256342B2 publication Critical patent/IL256342B2/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
IL256342A 2015-06-23 2016-06-22 מודל עכבר nsg מואנש עם שתלים ממקור של מטופלים שאינו תואם–hla IL256342B2 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562183386P 2015-06-23 2015-06-23
PCT/US2016/038622 WO2016209865A1 (en) 2015-06-23 2016-06-22 Non-hla matched humanized nsg mouse model with patient-derived xenograft

Publications (3)

Publication Number Publication Date
IL256342A IL256342A (he) 2018-02-28
IL256342B IL256342B (he) 2022-12-01
IL256342B2 true IL256342B2 (he) 2023-04-01

Family

ID=56404302

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256342A IL256342B2 (he) 2015-06-23 2016-06-22 מודל עכבר nsg מואנש עם שתלים ממקור של מטופלים שאינו תואם–hla

Country Status (13)

Country Link
US (3) US11248236B2 (he)
EP (1) EP3313175A1 (he)
JP (1) JP6813514B2 (he)
KR (2) KR102664078B1 (he)
CN (1) CN107920500B (he)
AU (3) AU2016284205B2 (he)
CA (1) CA2989839A1 (he)
HK (1) HK1255123A1 (he)
IL (1) IL256342B2 (he)
RU (1) RU2757421C2 (he)
SG (1) SG10201911694TA (he)
TW (1) TWI810145B (he)
WO (1) WO2016209865A1 (he)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102664078B1 (ko) 2015-06-23 2024-05-10 더 잭슨 래보라토리 환자-유래 이종이식을 가지는 hla-비매칭의 인간화된 nsg 마우스 모델
CN110740641A (zh) * 2016-11-30 2020-01-31 杰克逊实验室 具有改善的人先天免疫细胞发育的人源化小鼠模型
ES2983677T3 (es) 2017-04-17 2024-10-24 Jackson Lab Método de determinación de la toxicidad de un fármaco inmunomodulador para el uso en seres humanos
KR102226485B1 (ko) * 2017-05-29 2021-03-11 연세대학교 산학협력단 유방암 환자 종양 유래 이종이식 모델의 제조방법
WO2019006136A1 (en) * 2017-06-28 2019-01-03 Rutgers, The State University Of New Jersey ORGANOIDS DERIVED FROM A SINGLE VESIC CELL
US20210147810A1 (en) * 2017-06-28 2021-05-20 Rutgers, The State University Of New Jersey Single lung cell-derived organoids
WO2019032836A1 (en) * 2017-08-09 2019-02-14 The Jackson Laboratory IMMUNODEFICIENT MOUSE EXPRESSING THE HUMAN INTERLEUKINE 15
US20210153484A1 (en) * 2018-04-09 2021-05-27 The Wistar lnstitute Humanized Mouse Model
US12378574B2 (en) 2019-02-13 2025-08-05 The Jackson Laboratory Transgenic mouse models supporting innate immune function
CA3158295A1 (en) * 2019-11-15 2021-05-20 Board Of Regents, The University Of Texas System Humanized mouse model with human immune system
CN111485001A (zh) * 2020-04-14 2020-08-04 澎立生物医药技术（上海）有限公司 具有nk细胞及adcc能力的人源化免疫系统小鼠的构建方法
CN113264996A (zh) * 2020-04-30 2021-08-17 百奥赛图(北京)医药科技股份有限公司 一种人源化的非人动物及其制备方法和应用
CN111713450B (zh) * 2020-05-26 2022-07-12 上海交通大学医学院 一种慢性粒细胞白血病的pdx模型的建立方法
JP2023542539A (ja) * 2020-09-24 2023-10-10 ザ ジャクソン ラボラトリー 免疫細胞療法を評価するためのヒト化マウスモデル
CN116916748A (zh) * 2020-09-24 2023-10-20 杰克逊实验室 用于评估免疫细胞疗法的人源化小鼠模型
CN113951212A (zh) * 2020-10-30 2022-01-21 浙江省肿瘤医院 一种her2阳性胃癌耐药pdx模型及其构建方法与应用
KR102940881B1 (ko) 2020-11-06 2026-03-17 의료법인 성광의료재단 골수억제를 이용한 인간화 동물모델의 제조 방법
US20240041011A1 (en) * 2020-12-07 2024-02-08 The Jackson Laboratory Infectious disease mouse models
AU2022421979A1 (en) * 2021-12-22 2024-08-01 The Jackson Laboratory Humanized mouse models
EP4525609A1 (en) * 2022-05-19 2025-03-26 The Jackson Laboratory Transgenic mouse models of human adaptive and innate immunity and methods of use
CA3266908A1 (en) * 2022-09-08 2024-03-14 The Jackson Laboratory HUMANIZED IMMUNODEFICIENT MURINE MODELS
WO2024112158A1 (ko) * 2022-11-25 2024-05-30 가톨릭대학교 산학협력단 암환자 면역모사 아바타 시스템을 이용한 면역항암제 평가플랫폼
CN116138216A (zh) * 2022-12-12 2023-05-23 复旦大学附属肿瘤医院 一种氟尿嘧啶原发耐药直肠癌类器官移植瘤小鼠模型的建立与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60221987T2 (de) * 2001-06-22 2008-05-15 Stemcells, Inc., Palo Alto Le-zellen (liver engrafting cells), assays und verwendungen davon
DE602004025706D1 (he) 2003-07-10 2010-04-08 Central Inst Exper Animals
US20070118914A1 (en) * 2005-10-06 2007-05-24 Baylor Research Institute Oncohumouse
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
JP2014503217A (ja) * 2010-12-31 2014-02-13 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク マウスにおける自己ｔ細胞の生成
MX350385B (es) * 2011-02-15 2017-09-04 Regeneron Pharma Ratones de m-csf humanizada.
US20150283269A1 (en) * 2014-04-04 2015-10-08 Crown Bioscience Inc. Reconstituted human immune system in a patient derived xenograft mouse model
KR102664078B1 (ko) 2015-06-23 2024-05-10 더 잭슨 래보라토리 환자-유래 이종이식을 가지는 hla-비매칭의 인간화된 nsg 마우스 모델

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. N. VATAKIS ET AL,, ANTITUMOR ACTIVITY FROM ANTIGEN-SPECIFIC CD8 T CELLS GENERATED IN VIVO FROM GENETICALLY ENGINEERED HUMAN HEMATOPOIETIC STEM CELLS, 28 November 2011 (2011-11-28) *
E. BILLERBECK ET AL,, DEVELOPMENT OF HUMAN CD4+FOXP3+ REGULATORY T CELLS IN HUMAN STEM CELL FACTOR-, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-, AND INTERLEUKIN-3-EXPRESSING NOD-SCID IL2R NULL HUMANIZED MICE, 20 January 2011 (2011-01-20) *
MINAN WANG ET AL.,, ABSTRACT LB-050: PATIENT-DERIVED TUMOR XENOGRAFTS IN HUMANIZED NSG MICE: A MODEL TO STUDY IMMUNE RESPONSES IN CANCER THERAPY, 18 April 2015 (2015-04-18) *
YUN SHIN CHUNG ET AL,, CO-TRANSPLANTATION OF HUMAN FETAL THYMUS, BONE AND CD34+ CELLS INTO YOUNG ADULT IMMUNODEFICIENT NOD/SCID IL2R[GAMMA]NULL MICE OPTIMIZES HUMANIZED MICE THAT MOUNT ADAPTIVE ANTIBODY RESPONSES, 25 February 2015 (2015-02-25) *

Also Published As

Publication number Publication date
AU2022201100A1 (en) 2022-03-10
EP3313175A1 (en) 2018-05-02
RU2757421C2 (ru) 2021-10-15
CA2989839A1 (en) 2016-12-29
US20220127638A1 (en) 2022-04-28
AU2022201100B2 (en) 2024-04-04
AU2016284205A1 (en) 2018-01-18
JP6813514B2 (ja) 2021-01-13
US12595490B2 (en) 2026-04-07
IL256342B (he) 2022-12-01
SG10201911694TA (en) 2020-02-27
IL256342A (he) 2018-02-28
RU2018101316A (ru) 2019-07-24
KR20180019645A (ko) 2018-02-26
KR20240068768A (ko) 2024-05-17
AU2016284205B2 (en) 2021-12-02
WO2016209865A1 (en) 2016-12-29
US20180187210A1 (en) 2018-07-05
JP2018524981A (ja) 2018-09-06
CN107920500A (zh) 2018-04-17
RU2018101316A3 (he) 2019-11-11
TW201718852A (zh) 2017-06-01
KR102664078B1 (ko) 2024-05-10
AU2024201769A1 (en) 2024-04-04
US11248236B2 (en) 2022-02-15
TWI810145B (zh) 2023-08-01
HK1255123A1 (zh) 2019-08-02
US12577584B2 (en) 2026-03-17
HK1254127A1 (zh) 2019-07-12
CN107920500B (zh) 2021-02-05
AU2024201769B2 (en) 2025-08-21
US20220127639A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
US12595490B2 (en) Non-HLA matched humanized NSG mouse model with patient-derived xenograft
Judge et al. Minimal PD-1 expression in mouse and human NK cells under diverse conditions
US11207393B2 (en) Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
EP3433365B1 (en) T-cell exhaustion state-specific gene expression regulators and uses thereof
Lin et al. Human CD4 cytotoxic T lymphocytes mediate potent tumor control in humanized immune system mice
Maggi et al. T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma
JP2018519849A (ja) ヒト化マウス及びその使用
HK1254127B (zh) 具有患者衍生异种移植物的非hla匹配的人源化nsg小鼠模型
Chiossone et al. NK Cell-Based Therapies
Wierz Characterization of the Tumor Microenvironment in Chronic Lymphocytic Leukemia by Mass Cytometry: Implications for Immunotherapy
De La Rochere et al. A comprehensive analysis of humanized mouse models for the study of cancer immunotherapies
Sugimura Generation of functional macrophages from human embryonic organoids
WO2026084743A1 (en) Molecular engineering to enhance chimeric antigen receptor-mediated tumor immunotherapy